100,000 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Bought by Integral Health Asset Management LLC

Integral Health Asset Management LLC bought a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the medical research company’s stock, valued at approximately $13,688,000. Quest Diagnostics accounts for approximately 1.3% of Integral Health Asset Management LLC’s portfolio, making the stock its 25th biggest holding. Integral Health Asset Management LLC owned 0.09% of Quest Diagnostics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State of Alaska Department of Revenue lifted its holdings in Quest Diagnostics by 50.9% in the first quarter. State of Alaska Department of Revenue now owns 41,796 shares of the medical research company’s stock valued at $5,562,000 after acquiring an additional 14,090 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Quest Diagnostics by 5.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 135,148 shares of the medical research company’s stock valued at $18,634,000 after acquiring an additional 7,415 shares during the period. Scarborough Advisors LLC acquired a new stake in Quest Diagnostics in the fourth quarter valued at $1,562,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Quest Diagnostics by 16.5% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 131,329 shares of the medical research company’s stock valued at $17,481,000 after acquiring an additional 18,642 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Quest Diagnostics by 2.5% in the first quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock valued at $1,853,151,000 after acquiring an additional 345,754 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DGX. Piper Sandler raised their price target on Quest Diagnostics from $145.00 to $150.00 and gave the company a “neutral” rating in a research report on Monday, July 29th. Robert W. Baird raised their price target on Quest Diagnostics from $153.00 to $154.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. StockNews.com upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. raised their price target on Quest Diagnostics from $152.00 to $155.00 and gave the company a “neutral” rating in a research report on Thursday, May 30th. Finally, Evercore ISI began coverage on Quest Diagnostics in a research report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price target for the company. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $154.33.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Mark E. Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total value of $60,093.60. Following the transaction, the senior vice president now directly owns 5,019 shares of the company’s stock, valued at approximately $718,118.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Karthik Kuppusamy sold 1,990 shares of Quest Diagnostics stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total value of $304,987.40. Following the transaction, the senior vice president now directly owns 11,459 shares of the company’s stock, valued at approximately $1,756,206.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mark E. Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total value of $60,093.60. Following the completion of the transaction, the senior vice president now directly owns 5,019 shares in the company, valued at $718,118.52. The disclosure for this sale can be found here. 0.79% of the stock is owned by company insiders.

Quest Diagnostics Trading Down 1.4 %

Quest Diagnostics stock opened at $152.99 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.91 and a debt-to-equity ratio of 0.57. The stock has a market cap of $17.00 billion, a PE ratio of 20.59, a P/E/G ratio of 2.80 and a beta of 0.89. The stock has a 50-day moving average price of $150.61 and a 200 day moving average price of $141.09. Quest Diagnostics Incorporated has a 52 week low of $119.59 and a 52 week high of $159.36.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.31 by $0.04. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.39 billion. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. The firm’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.30 EPS. Equities research analysts predict that Quest Diagnostics Incorporated will post 8.89 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.96%. The ex-dividend date is Friday, October 4th. Quest Diagnostics’s dividend payout ratio (DPR) is 40.38%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.